Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Implementation of a microwave-assisted tissue-processing system and an automated embedding system for breast needle core biopsy samples: morphology, immunohistochemistry, and FISH evaluation.

Pegolo E, Pandolfi M, Di Loreto C.

Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):362-70. doi: 10.1097/PAI.0b013e318270f869.

PMID:
23060302
[PubMed - indexed for MEDLINE]
2.

Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination.

Pegolo E, Machin P, Riosa F, Bassini A, Deroma L, Di Loreto C.

Cancer Cytopathol. 2012 Jun 25;120(3):196-205. doi: 10.1002/cncy.20206. Epub 2012 Feb 1.

PMID:
22298467
[PubMed - indexed for MEDLINE]
3.

Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization.

Vogel UF.

Diagn Pathol. 2010 Jul 29;5:50. doi: 10.1186/1746-1596-5-50.

PMID:
20670419
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.

Kinsella MD, Nassar A, Siddiqui MT, Cohen C.

Int J Clin Exp Pathol. 2012;5(6):530-6. Epub 2012 Jul 29.

PMID:
22949935
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.

Monaco SE, Wu Y, Teot LA, Cai G.

Diagn Cytopathol. 2013 Apr;41(4):308-15. doi: 10.1002/dc.21841. Epub 2011 Nov 1.

PMID:
22045649
[PubMed - indexed for MEDLINE]
6.

A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs RR.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):94-102.

PMID:
17536315
[PubMed - indexed for MEDLINE]
7.

Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.

Shabaik A, Lin G, Peterson M, Hasteh F, Tipps A, Datnow B, Weidner N.

Diagn Cytopathol. 2011 May;39(5):328-32. doi: 10.1002/dc.21389.

PMID:
21488175
[PubMed - indexed for MEDLINE]
8.
9.

Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.

Müller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ, Kristiansen G, Petry C, Dietel M, Denkert C.

Diagn Mol Pathol. 2011 Mar;20(1):1-10. doi: 10.1097/PDM.0b013e3181e3630c.

PMID:
21326033
[PubMed - indexed for MEDLINE]
11.

Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2.

Cano G, Milanezi F, Leitão D, Ricardo S, Brito MJ, Schmitt FC.

Diagn Cytopathol. 2003 Oct;29(4):207-11.

PMID:
14506673
[PubMed - indexed for MEDLINE]
12.

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.

D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.

Am J Surg Pathol. 2010 Apr;34(4):575-81. doi: 10.1097/PAS.0b013e3181d65639.

PMID:
20216378
[PubMed - indexed for MEDLINE]
13.

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.

Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY.

BMC Cancer. 2010 Oct 7;10:534. doi: 10.1186/1471-2407-10-534.

PMID:
20925963
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status.

Bédard YC, Pollett AF, Leung SW, O'Malley FP.

Acta Cytol. 2003 Nov-Dec;47(6):979-84.

PMID:
14674066
[PubMed - indexed for MEDLINE]
15.

An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.

O'Grady A, Allen D, Happerfield L, Johnson N, Provenzano E, Pinder SE, Tee L, Gu M, Kay EW.

Appl Immunohistochem Mol Morphol. 2010 Dec;18(6):489-93. doi: 10.1097/PAI.0b013e3181e3d893.

PMID:
20661132
[PubMed - indexed for MEDLINE]
16.

Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.

Kumar SK, Gupta N, Rajwanshi A, Joshi K, Singh G.

Cytopathology. 2012 Jun;23(3):181-6. doi: 10.1111/j.1365-2303.2011.00853.x. Epub 2011 Mar 6.

PMID:
21375607
[PubMed - indexed for MEDLINE]
17.

Cytologic evaluation of prognostic markers in breast carcinoma.

Jayaram G, Elsayed EM.

Acta Cytol. 2005 Nov-Dec;49(6):605-10.

PMID:
16450899
[PubMed - indexed for MEDLINE]
18.
19.

Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.

Lee AH, Key HP, Bell JA, Hodi Z, Ellis IO.

Histopathology. 2012 May;60(6):880-4. doi: 10.1111/j.1365-2559.2011.04144.x. Epub 2012 Feb 9.

PMID:
22320892
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk